MedTrace Logo

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

NCT01585298 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6998

Last updated 2019-09-23

Study results available
· View outcomes & findings →

Summary

This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.

Conditions

Interventions

DRUG

FTY720

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-29
Primary Completion
2016-12-12
Completion
2016-12-12

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01585298 on ClinicalTrials.gov